An exploratory study on the safety and efficacy of 177Lu-FAP-2286 versus 225Ac-FAP-2286 therapy for FAP-positive advanced pancreatic ductal adenocarcinoma (ChiCTR) - Oct 16, 2026 - P=N/A | N=60 | Not yet recruiting | Sponsor: The affiliated hospital of southwest medical university; The affiliated hospital of southwest medical university
New trial • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • CA 19-9
|